Analysts Predict Q1 2026 Earnings for Black Diamond Therapeutics
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) has received its Q1 2026 earnings forecast from equities research analysts at Wedbush. According to analyst R. Driscoll, the company is expected to report earnings per share (EPS) of ($0.22) for the quarter. Wedbush has given Black Diamond Therapeutics an “Outperform” rating with a price target of $11.00.
The current full-year earnings estimate for Black Diamond Therapeutics stands at ($1.30) per share. Additionally, Wedbush has projected:
- Q2 2026 EPS: ($0.23)
- Q3 2026 EPS: ($0.23)
- Q4 2026 EPS: ($0.24)
Black Diamond Therapeutics’ Latest Financial Performance
On March 6, 2025, Black Diamond Therapeutics reported its quarterly earnings with an EPS of ($0.28), beating analysts’ expectations of ($0.31) by $0.03.
Separately, Stifel Nicolaus recently adjusted its price target for BDTX, lowering it from $16.00 to $15.00 while maintaining a “Buy” rating. According to MarketBeat, the stock currently has an average rating of “Buy”, with a target price of $14.40.
Stock Performance & Market Position
- Current Price: $1.88 (as of March 10, 2025)
- Market Capitalization: $106.38 million
- P/E Ratio: -1.41
- Beta Value: 2.52
- 52-Week Range: $1.77 – $7.66
- 50-Day Moving Average: $2.23
- 200-Day Moving Average: $3.16
Institutional Investors & Hedge Fund Activity
Several institutional investors have increased or adjusted their holdings in Black Diamond Therapeutics:
- Intech Investment Management LLC acquired a new position in Q3 2025 worth $56,000.
- Charles Schwab Investment Management Inc. increased its holdings by 6.9%, now owning 109,224 shares valued at $475,000.
- FMR LLC invested $779,000 in Black Diamond Therapeutics.
- MetLife Investment Management LLC expanded its holdings by 129.1%, adding 12,557 shares.
- Walleye Capital LLC took a new stake worth $49,000.
Currently, 95.47% of Black Diamond Therapeutics’ shares are held by institutional investors and hedge funds.
About Black Diamond Therapeutics
Black Diamond Therapeutics is a clinical-stage oncology company specializing in precision medicine for cancer treatment. The company’s lead drug candidate, BDTX-1535, is a brain-penetrant EGFR MasterKey inhibitor currently in:
- Phase 2 clinical trials for EGFR-mutant non-small cell lung cancer (NSCLC)
- Phase 1 clinical trials for glioblastoma
Final Thoughts
As Black Diamond Therapeutics continues its clinical advancements and maintains strong backing from institutional investors, its stock remains a key focus for market analysts. With a consistent buy rating and a target price of $14.40, investors are closely watching the company’s progress in oncology drug development.